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Introduction
Persistent inflammation and immune dysfunction play an important role in the development of  non-
AIDS–related comorbidities in people living with HIV (PLHIV). Those include cardiovascular disease 
(CVD), neurocognitive dysfunction, and cancer (1–4). Reducing inflammation is considered an attractive 
therapeutic target to reduce the burden of  non-AIDS–related events. However, immune dysfunction and 
persistent inflammation in PLHIV are complex processes that are still incompletely understood. These 
involve changes in the adaptive immune system, including dysfunction and senescence of  T cell lympho-
cytes (5), as well as changes in the innate immune system. Mediators of  the latter, including soluble CD14 
(sCD14), sCD163, and high-sensitivity C-reactive protein (hsCRP), are indicative of  persistent immune 
activation and are associated with non-AIDS–related events (6–8).
Ongoing exposure to microbial products, for example, by CMV, continuing HIV replication, or microbial 
translocation, may be one of the drivers of persistent inflammation (2, 9–12). Increased inflammation can also 
result from a functional adaptation of innate immune cells induced by epigenetic reprogramming, a process 
termed “trained immunity” (13–16). Trained immunity is recognized to play an important beneficial role in 
Chronic inflammation and immune dysfunction play a key role in the development of non-AIDS–
related comorbidities. The aim of our study was to characterize the functional phenotype of 
immune cells in people living with HIV (PLHIV). We enrolled a cross-sectional cohort study of PLHIV 
on stable antiretroviral therapy and healthy controls. We assessed ex vivo cytokine production 
capacity and transcriptomics of monocytes and T cells upon bacterial, fungal, and viral stimulation. 
PLHIV exhibited an exacerbated proinflammatory profile in monocyte-derived cytokines, but not 
in lymphocyte-derived cytokines. Particularly, the production of the IL-1β to imiquimod, E. coli 
LPS, and Mycobacterium tuberculosis was increased, and this production correlated with plasma 
concentrations of high-sensitivity C-reactive protein and soluble CD14. This increase in monocyte 
responsiveness remained stable over time in subsequent blood sampling after more than 1 year. 
Transcriptome analyses confirmed priming of the monocyte IL-1β pathway, consistent with a 
monocyte-trained immunity phenotype. Increased plasma concentrations of β-glucan, a well-
known inducer of trained immunity, were associated with increased innate cytokine responses. 
Monocytes of PLHIV exhibited a sustained proinflammatory immune phenotype with priming of the 
IL-1β pathway. Training of the innate immune system in PLHIV likely plays a role in long-term HIV 
complications and provides a promising therapeutic target for inflammation-related comorbidities.
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host defense processes, but it may also contribute to conditions like atherosclerosis or type 2 diabetes mellitus 
(17, 18). Whether trained immunity contributes to persistent inflammation in PLHIV is currently unknown.
The Human Functional Genomics Project (HFGP) aims to investigate variation in the immune 
responses (19). Studies in HFGP cohorts in healthy individuals have yielded different novel insights in the 
genetic and nongenetic regulation of  inflammatory cytokine responses in response to microbial ligands 
(20–23). We established a HFGP cohort of  Dutch PLHIV, and in this cohort we describe alterations in 
the function and phenotype of  PBMCs by using an integrative approach of  functional and transcriptional 
analyses. We also explored underlying mechanisms of  the inflammatory monocyte profile, including the 
possible contribution of  exposure to microbial translocation, CMV seropositivity, and HIV reservoir size.
Results
Characteristics. A total of 211 PLHIV on combination antiretroviral therapy (cART) and 56 HIV-uninfected con-
trols were included in the analyses. Baseline characteristics are shown in Table 1. Compared with the healthy 
controls, PLHIV were more often men (91.5% vs. 60.7%, P < 0.001) and of older age (median [IQR] age of  
52.5 [13.2] vs. 30.0 [27.1] years, P < 0.0001). The median (IQR) duration of cART use in PLHIV was 6.6 years 
(4–12 years), and 89% were virally suppressed (HIV viral copies ≤ 50 copies/mL) for longer than 1 year.
Circulating inflammatory markers and innate cytokine responses. We first measured concentrations of  circu-
lating inflammatory markers. Compared with healthy controls, PLHIV had significantly higher concentra-
tions of  sCD14, hsCRP, IL-18, IL-18–binding protein (IL-18BP), and IL-6 (Figure 1, A–G). These differ-
ences remained after adjusting for age, sex, BMI, or seasonality (Figure 1A). Concentrations of  adipokines 
were similar between groups after correction (Figure 1A).
Next, we analyzed functional changes in the innate and adaptive immune response. PBMCs were incu-
bated with 12 stimuli (4 bacterial, 3 fungal, 1 viral, and 6 TLR ligands), followed by measurement of  different 
monocyte-derived (IL-6, IL-1β, and TNF-α) and lymphocyte-derived (IL-17, IL-22, and IFN-γ) proinflam-
matory cytokines, as well as antiinflammatory cytokines (IL-10 and IL-1 receptor antagonist, IL-1Ra) in the 
supernatant. We observed markedly increased monocyte-derived cytokine responses in PLHIV, especially 
IL-1β responses upon stimulation with LPS (TLR4), imiquimod (TLR7), and Mycobacterium tuberculosis (Fig-
ure 2, A, C, and D). Production of  TNF-α and IL-6 was also increased in PLHIV (Figure 2, A and E), except 
for lower production in response to Staphylococcus aureus (TNF-α) and Candida albicans (IL-6; Figure 1, F 
and G). This increased proinflammatory cytokine response in PLHIV was not associated with a concurrent 
increase in the antiinflammatory cytokines IL-1Ra or IL-10. However, the release of  IL-1Ra by unstimulated 
cells was higher in PLHIV (Figure 2H), which is consistent with increased basal IL-1β production (Figure 
2A). The number of  monocytes in the isolated PBMCs (Supplemental Figure 1, A and B; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.145928DS1) may influence 
cytokine production, but adjusting for the monocyte fraction in PBMCs did not significantly alter the out-
come (Supplemental Figure 1C; T cell–derived cytokine responses were generally lower for most stimuli in the 
PLHIV cohort; Supplemental Figure 2). These differences were abrogated after adjustment for age, sex, and 
seasonality (Figure 1A), except for IFN-γ responses to M. tuberculosis and C. albicans hyphae (Figure 2, A and 
B). There were no associations between cytokine production capacity and smoking or different HIV-specific 
traits, including recent CD4 cell count, CD4/CD8 cell ratio, CD4 nadir, cART regimen, or comedication 
(metformin, statins, or aspirin) (Supplemental Figure 3).
Next, we assessed associations between innate cytokine responses, circulating inflammatory markers, and 
monocyte phenotypes (Figure 3, A–I). Increased ex vivo cytokine responses were associated with persistent 
inflammation. For example, we found positive associations between IL-6 responses and circulating hsCRP (Fig-
ure 3, A and I) and between LPS-induced IL-1β responses and plasma sCD14 and IL-18BP (Figure 3, A and 
D). In addition, nonclassical and intermediate monocyte subsets (Supplemental Figure 4, A–F), which are con-
sidered proinflammatory monocyte phenotypes, correlated with higher IL-1β and IL-6 production after LPS or 
imiquimod, respectively (intermediate monocytes vs. LPS-induced IL-1β r = 0.23, P < 0.001; Figure 3, A–C) 
(24). Taken together, we show that PLHIV have an altered innate immune profile with markedly elevated mono-
cyte cytokine responses, particularly IL-1β, which correlates with blood biomarkers of persistent inflammation.
Increased IL-1β production capacity of  PLHIV was stable over time. We then assessed the longevity of  the 
elevated monocyte-derived cytokine responses. We resampled 28 PLHIV, men older than 45 years of  age, 
after more than 1 year and stratified them on the basis of  their initial IL-1β production capacity in a group 
of  low IL-1β–producers (lowest quartile) and high IL-1β–producers (highest quartile). Fourteen age- and 
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sex-matched uninfected controls were enrolled concurrently (Supplemental Table 1). Upon resampling, those 
assigned to the high IL-1β–producer group still exhibited higher IL-1β and IL-6 production compared with 
participants in the low IL-1β–producer group and matched healthy controls, suggesting that the enhanced 
monocyte responsiveness was stable over time (Figure 4, A and B). TNF-α followed a similar but nonsig-
nificant pattern (P = 0.075; Figure 4C). To examine if  the presence of  T lymphocytes affected the outcome, 
we isolated monocytes using magnetic beads (purity > 95%; Supplemental Figure 4G) and repeated the 
stimulation experiments. We found that IL-1β production remained increased, suggesting that the elevated 
monocyte-derived cytokine response was due to an enhanced functional state of  the monocytes themselves.
Enhanced proinflammatory functional state of  monocytes. Based on this enhanced functional state, we postulat-
ed that a trained immunity functional phenotype (13, 14) contributes to the enhanced monocyte responsiveness 
in PLHIV. Hence, we isolated monocytes from 8 PLHIV and 4 age- and sex-matched uninfected controls and 
analyzed their transcriptomes by RNA-Seq. Using principal component analysis, we observed clustering of  
Table 1. Baseline characteristics
PLHIV (n = 211) Healthy controls (n = 56)
Sex (% male/female) 193/18 (91.5/8.5) 34/22 (60.7/39.3)A
Age (years, mean [SD]) 51.4 (10.8) 39.9 (17.3)B
BMI (kg/m2, mean [SD]) 24.5 (3.6) 24.1 (3.1)
HIV infection duration (years, median [IQR]) 8.5 [4.9, 14.2]
Way of transmission (%)
 Heterosexual 9 (4.3)
 IDU 3 (1.4)
 MSM 159 (75.4)
 Other/unknown 40 (19.0)
CD4 nadir (106 cells/mL; median [IQR]) 250.0 [135.0, 360.0]
CD4 count (106 cells/mL; median [IQR]) 660.0 [480.0, 810.0]
HIV load below 200 copies/mL (n [%]) 211 (100)
HIV load below 50 copies/mL for >1 year (n [%]) 188 (89%)
CD4/CD8 ratio (median [IQR]) 0.8 [0.6, 1.1]
cART duration (years; median [IQR]) 6.6 [4.2, 11.8]
cART regimen
NRTI use (%) 203 (96.2)
NtRTI use (%) 99 (46.9)
NNRTI use (%) 63 (29.9)
PI use (%) 32 (15.2)
Maraviroc use (%) 3 (1.4)
INSTI use (%) 141 (66.8)
Active smoking, n/N (%) 63 (29.9) 2 (3.6)B
Heavy drinking (%)C 28 (13.3) 11 (19.6)
Regular substance use (%)D 61 (28.9) 3 (5.4)B
Hypercholesterolemia (%) 58 (27.5)
Hypertension (%) 41 (19.4)
Diabetes mellitus (%) 9 (4.3)
No cardiovascular risk factors (%) 50 (23.7)
Statins (%) 58 (27.5)
Aspirin (%) 19 (9.0)
Metformin (%) 9 (4.3)
ASignificantly different between cohorts using 2-tailed Student’s t test. BSignificantly different between 
cohorts using χ2 test. CClassified according to the CDC definition as follows: for men, ≥15 drinks/week, and 
for women, ≥8 drinks/week (76). DDefined as use of any psychoactive substance (with the exception of 
alcohol and tobacco) during periods ≥ 1 time per week including ≥ 1 time during the 30 days prior to the 
study visit. BMI, body mass index; IDU, intravenous drug use; MSM, men who have sex with men; cART, 
combination antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NtRTI, nucleotide 
reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor; INSTI, integrase inhibitor.
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the PLHIV and controls (Figure 5A). This clustering was even more pronounced when monocytes were dif-
ferentiated toward macrophage phenotype by culture for 24 hours in serum-free medium (RPMI; Figure 5B) 
and was also observed using hierarchical clustering (Figure 5C). Gene ontology analysis of 303 upregulated 
and 30 downregulated genes (Supplemental Table 5) showed that proinflammatory pathways were upregulat-
ed in PLHIV, including the “inflammatory response,” “regulation of innate immune response,” and “IL-1β 
production” pathways (Figure 5, D and E). Among the upregulated genes in these pathways were intracellular 
signaling proteins and inflammasome-related molecules (e.g., NLRP3, STAT1), cytokines (e.g., IL1B, CCL2, 
MMP9, IL1RN), and pattern recognition receptors (e.g., TLR2, TLR4, TLR7, NOD2), underlining the broad 
upregulation of inflammatory pathways in PLHIV on long-term cART.
Enhanced IL-1β gene expression in monocytes of  PLHIV. The release of  active IL-1β from blood monocytes 
involves a priming signal that is mostly transcriptionally driven, which results in the synthesis of  the IL-1β 
precursor (pro–IL-1β). This precursor is subsequently processed via caspase-1 into active IL-1β (25). Using 
real-time quantitative PCR (RT-qPCR) on monocytes stimulated with IMQ, we found that the IL1B (gene 
encoding for pro–IL-1β) RNA expression was higher in monocytes from PLHIV compared with controls 
(Figure 6A; P = 0.021). IL6 mRNA followed a similar trend (Figure 6B; P = 0.027), whereas TNFA expres-
sion did not (data not shown; P = 0.74). Additionally, we measured intracellular pro–IL-1β and active IL-1β 
protein by ELISA, and both were significantly elevated in PLHIV (Figure 6, D and E). The inflammasome 
promotes the proteolytic cleavage of  pro–IL-1β into active IL-1β, resulting in reduced pro–IL-1β/active 
IL-1β ratios in situations with increased caspase-1 activity (25). Instead, we observed a trend toward an 
increased ratio of  intracellular pro–IL-1β to active IL-1β (Figure 6F) in the high IL-1β–producing PLHIV 
and no differences in levels of  NLRP3 expression (Figure 6C). Together, these results demonstrate that the 
Figure 1. Circulating factors in PLHIV versus uninfected HCs. (A) Circulating factors in PLHIV and uninfected controls. Crude model is linear regres-
sion after inverse rank-based transformation. Adjusted model included age, sex, and seasonality as covariates. Red depicts the marker is significantly 
increased in PLHIV; blue depicts the marker is decreased in PLHIV compared with HCs. All P values are FDR corrected (Benjamini-Hochberg method). 
(B–G) Box plots depicting circulating factors of inflammation stratified by cohort; PLHIV (blue), uninfected controls (yellow). P values are calculated using 
2-tailed Student’s t test. Box plots are depicted according to Tukey; median (line), IQR (edge of box plot), range (whiskers), and outliers 3 times IQR are 
depicted as dots. All plots include data from PLHIV (n = 211) and HCs (n = 56). PLHIV, people living with HIV; HCs, healthy controls; hsCRP, high-sensitivity 
C-reactive protein; sCD14, soluble CD14; sCD163, soluble CD163; IL-18BP, IL-18–binding protein.
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enhanced IL-1β transcription, rather than increased processing through caspase-1, was the biological pro-
cess that primarily drove the increased IL-1β production in PLHIV.
β-Glucan exposure induced a proinflammatory monocyte phenotype. We next examined possible pathways underly-
ing the proinflammatory monocyte phenotype in PLHIV. Persistent exposure to microbial ligands derived from 
gut microbes, CMV, or HIV itself has been suggested to play a role in the persistent inflammation in PLHIV 
(2, 9–12). We postulated that these factors also play a role in the proinflammatory monocyte phenotype. We, 
therefore, first assessed whether innate cytokine responses were associated with parameters of the HIV viral reser-
voir. The HIV reservoir was assessed by analyzing CD4+ cell–associated HIV-1 DNA (CA-DNA) and CA-RNA. 
In virally suppressed patients, the CA-DNA roughly equals the integrated HIV-1 DNA, being replication 
Figure 2. Cytokine production capacity in PLHIV versus uninfected HCs. (A) Ex vivo cytokine production capacity between PLHIV and HCs after 24 hours 
(in case of IL-1β, TNF-α, IL-6, IL-10, and IL-1Ra) and 7 days stimulation (IL-22, IL-17, and IFN-γ). FDR-corrected (Benjamini-Hochberg method) P values are 
depicted from an adjusted model that included age, sex, seasonality as covariates. Red depicts a significantly higher cytokine production capacity, and 
blue depicts a lower cytokine production capacity in PLHIV compared with HCs. (B–H) Box plots depicting ex vivo cytokine production capacity stratified  
by cohort. PLHIV depicted in blue and uninfected controls in yellow. P values, depicted in box plots, were calculated using 2-tailed Student’s t test after log 
transformation. All box plots are depicted according to Tukey; median (line), IQR (edge of box plot), range (whiskers), and outliers 3 times IQR are depicted 
as dots. All plots include data from PLHIV (n = 211) and HCs (n = 56). PLHIV, people living with HIV; HCs, healthy controls; oxLDL, oxidized LDL; Pam3Cys, 
synthetic TLR2 ligand; Poly IC, TLR3 ligand; imiquimod, TLR7 ligand.
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competent or not (26), whereas CA-RNA is associated with recent HIV-1 transcriptional activity and serves as a 
proxy for the active proviral reservoir (27). Although CA-DNA levels in CD4+ T cells were associated with plasma 
IL-6 concentrations (Figure 7A), there was no association between IL-1β cytokine responses (Supplemental Fig-
ure 5) or plasma sCD14 concentrations and HIV-1 CA-DNA or CA-RNA levels in our cohort (Figure 7, B–H).
Figure 3. Cytokine production capacity versus circulating factors. (A) Correlation plot with adjusted P value shown after correcting for age, sex, and sea-
sonality as covariates. Red depicts a significant positive correlation and blue depicts a negative correlation within PLHIV. All P values were FDR corrected 
per circulating factor. (B–I) Correlation plots without cofactor adjustment. Pearson’s coefficient (r) with P value after log transformation is shown. All plots 
include data from PLHIV (n = 211) and HCs (n = 56). PLHIV, people living with HIV; HCs, healthy controls; oxLDL, oxidized LDL; Pam3Cys, synthetic TLR2 
ligand; Poly IC, TLR3 ligand; imiquimod, TLR7 ligand; hsCRP, high-sensitivity C-reactive protein; sCD14, soluble CD14; sCD163, soluble CD163; IL-18BP, IL-18–
binding protein. *P < 0.05 after FDR correction.
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Next, we assessed associations between cytokine responses and CMV seropositivity. In total, 198 of  
211 (93.8%) participants were CMV seropositive. There were no differences in IL-1β cytokine respons-
es, sCD14 concentrations, or HIV-1 CA-DNA between CMV-seropositive versus -seronegative individuals 
(Figure 7, I–L, and Supplemental Figure 5).
Another source of  chronic microbial ligand exposure in PLHIV is increased microbial translocation 
(9). Plasma concentrations of  intestinal fatty acid–binding protein (iFABP), a marker for microbial trans-
location, were significantly increased in PLHIV compared with controls (Figure 7M). We found a modest 
negative correlation of  iFABP concentrations with IL-1β cytokine responses (Figure 7, N and O) but no 
correlation with sCD14 concentrations (Figure 7P).
Figure 4. Ex vivo cytokine production capacity of monocytes in a validation cohort. (A) IL-1β production upon 24 hours’ stim-
ulation with imiquimod (1 μg/mL), LPS (100 ng/mL), or M. tuberculosis (1 μg/mL) in PBMCs or monocyte-only culture (magnet-
ic beads CD14+ isolation). (B) IL-6 production upon imiquimod stimulation. (C) TNF-α production upon imiquimod stimulation. 
All data are stratified by HCs (n = 14), PLHIV low initial IL-1β–producers (n = 13), and PLHIV high IL-1β–producers (n = 15). All box 
plots are depicted according to Tukey; median (line), IQR (edge of box plot), range (whiskers), and outliers 3 times IQR (dots). A 
Kruskal-Wallis test was performed with a post hoc testing when the P value was below 0.05. Post hoc testing was performed 
by using a Mann-Whitney U test on the comparison PLHIV high vs. HCs and PLHIV high vs. PLHIV low. A Bonferroni’s multi-
ple-testing correction was used by setting the significance level at P < 0.025 for post hoc analysis. *P < 0.025, **P < 0.001, #P 
< 0.05 (above multiple-testing threshold), ns, nonsignificant. PLHIV, people living with HIV; HCs, healthy controls.
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Increased intestinal translocation may also increase circulating concentrations of  β-glucan, which is a 
well-known inducer of  trained immunity (28). We therefore determined serum β-glucan concentrations in 
the subsequent cohort of  28 PLHIV and 12 controls. Compared with controls (4 of  14, 29%), a significantly 
higher proportion of  PLHIV (16 of  28, 57%), and especially those in the high IL-1β–producer group (11 of  
15, 73%), had detectable β-glucan in serum (Figure 8, A and B). Individuals with detectable serum β-glucan 
had elevated IL-1β production (Figure 8, C and D) and showed increased IL1B gene expression (Figure 8E) 
and increased intracellular pro–IL-1β upon stimulation (Figure 8F). Concurrently, IL-1Ra production was 
increased in PLHIV with detectable β-glucan concentrations (Figure 8G). A similar, nonsignificant trend 
was observed for IL-6 and TNF-α responses (Figure 8, H–L). Next, using a well-established in vitro training 
protocol of  trained immunity (29), we confirmed that prestimulation of  adherent monocytes with β-glucan 
resulted in a pronounced enhancement of  IL-6 release upon restimulation with LPS on day 6 (Figure 8M). 
We also investigated the effects of  prestimulation with LPS. As previously reported, prestimulation with 
LPS induced immune tolerance (Figure 8D) (15). Taken together, these findings suggest that circulating 
β-glucan was a possible driver of  the proinflammatory immune phenotype of  monocytes in PLHIV.
Discussion
In this study, we investigated the functional phenotype of circulating immune cells in a cohort of PLHIV on sta-
ble cART. We show that PLHIV exhibited a sustained elevation in monocyte cytokine responsiveness, whereas 
lymphocyte-derived cytokine responses were mostly unaffected. Our immune profiling data, which included 
transcriptome analysis of circulating monocytes, further showed an increased expression and activation of the 
IL-1β pathway. HIV infection is associated with increased microbial translocation (9), and we identified a role 
for elevated circulating β-glucan concentrations in the altered inflammatory monocyte phenotype in PLHIV.
These data corroborate findings from earlier, smaller studies in PLHIV, which reported an increased 
production of  proinflammatory cytokines to stimulation with ligands of  TLR4 (30, 31) or TLR7 (32, 33) 
or M. tuberculosis (34). The increased monocyte-derived cytokine responsiveness in our PLHIV cohort was 
associated with increased plasma concentrations of  different circulating inflammatory markers, such as 
hsCRP, sCD14, IL-18, and IL-6, suggesting a functional link between changes in the innate immune pro-
file and systemic inflammation in PLHIV. Remarkably, HIV infection had little effect on lymphocyte-de-
rived cytokine responses, despite the fact that alterations in T cell immune phenotype have been described 
in long-term virally suppressed PLHIV (35, 36). Previous research in HFGP cohorts of  HIV-uninfected 
individuals showed that age, environmental, microbial, and genetic factors have a clear impact on the 
function of  circulating T cells (21–23, 37).
The observed intrinsic proinflammatory phenotype of  monocytes in PLHIV was stable over time and 
associated with upregulation of  proinflammatory pathways, most notably the IL-1β pathway. This corrob-
orates a recent study showing a pronounced proinflammatory phenotype, including upregulation of  IL1B, 
of  monocyte-derived macrophages in PLHIV (38). Long-term epigenetic reprogramming of  monocytes in 
response to microbes has been termed trained immunity. This functional adaptation of  monocytes enables 
a greater response when subjected to a secondary stimulus as a protective mechanism against a secondary 
infection (14–16). Nonetheless, a trained immunity phenotype of  monocytes has also been related to condi-
tions such as CVDs and diabetes (39–42). In PLHIV, altered epigenetic profiles such as DNA methylation 
have been reported (43–45). Specific DNA methylation patterns in PLHIV were associated with progressive 
aging and non-AIDS–related comorbidities, such as insulin resistance, neurocognitive disorders, and chronic 
kidney disease (17, 46–48). Interestingly, HIV/SIV DNA vaccination was recently shown to induce a trained 
immunity phenotype in vivo through upregulation of  IL-1β–related genes (49). This upregulation correlat-
ed with protection against subsequent SIV infection in macaques. Furthermore, HIV-1 itself  has also been 
shown to increase IL-6 production via epigenetic modification of  STAT3 in microglial cells (50).
Although epigenetic modification has been shown to underlie the trained immunity phenotype, we 
did not determine epigenetic changes in the current study. Future studies are warranted to investigate the 
epigenetic processes underlying the trained immunity phenotype reported here.
Figure 5. Transcriptome analysis of monocytes. (A) PCA plot of transcriptome of monocytes from PLHIV and HCs directly after isolation. (B) PCA plot of tran-
scriptome of monocytes from PLHIV and HCs after 24 hours’ macrophage differentiation in medium only. (C) Hierarchical clustering plot (PLHIV vs. HCs). (D) Gene 
ontology of differentially expressed genes (PLHIV vs. HCs) including adjusted P value and gene count. (E) Top pathways of gene ontology plot after macrophage 
differentiation (gene ontology interaction terms). PLHIV, n = 8; HC, n = 4. PCA, principal component analysis; PLHIV, people living with HIV; HCs, healthy controls.
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Another question concerned the identification of  the possible mechanisms responsible for the observed 
changes in innate immune responses. CMV (10), microbial translocation (9), and HIV reservoir (11) have 
each been related to persistent inflammation in PLHIV. However, our data did not show a positive correla-
tion between monocyte responsiveness and CMV seropositivity, levels of  iFABP (microbial translocation 
marker), or parameters of  the HIV reservoir. Although we do not exclude a possible accessory role for 
these markers of  microbial exposure, we did find an association of  circulating β-glucan concentrations and 
IL-1β responsiveness. β-Glucan is a component of  the cell wall of  fungi and is known to be a strong inducer 
of  trained immunity (16). Furthermore, IL-1β signaling is reported to be important in β-glucan–induced 
trained immunity in vivo (51). Our present data corroborate earlier reports that increased circulating β-glu-
can concentrations can be found in virally suppressed PLHIV (28, 52, 53). Acute HIV infection leads to 
an early and pronounced loss of  mucosal Th17 CD4+ T cells (54). This cellular compartment is critical 
for regulation of  mucosal host defense against Candida and regulation of  epithelial cell permeability (55). 
Increased levels of  other microbial products, including LPS, have also been reported in PLHIV (28, 56). 
However, in contrast to β-glucan, LPS generally induces immune tolerance, even at low concentrations (15, 
16), a notion we confirmed in vitro. This notion is supported by our observation that microbial integrity, as 
measured by iFABP, is associated with decreased monocyte responsiveness. An HIV infection is associated 
with alterations in the bacterial gut microbiome composition and these changes play a role in the incidence 
of  comorbidities and inflammation (2, 57, 58). Although studies on the mycobiome in PLHIV are limited, 
fungal dysbiosis with a high prevalence of  Candida species has been found in stool samples of  PLHIV (59). 
Furthermore, our data showed lower IL-6 and higher IL-10 production by monocytes upon Candida stim-
ulation in PLHIV compared with uninfected controls, suggesting an altered fungal immune response. This 
Figure 6. IL1B gene expression and intracellular pro–IL-1β. (A) IL1B gene expression after imiquimod 1 μg/mL stimulation 
depicted as FC from medium (RPMI). (B) IL6 gene expression after imiquimod stimulation depicted as FC from medium. 
(C) NLRP3 gene expression (by ΔCT) in RPMI. (D) Intracellular levels of pro–IL-1β protein after imiquimod stimulation. (E) 
Intracellular mature IL-1β protein after imiquimod stimulation. (F) Ratio of intracellular pro–IL-1β vs. IL-1β after imiquimod 
stimulation protein. All data are stratified by HCs (n = 14), PLHIV low initial IL-1β–producers (n = 13), and PLHIV high IL-1β–
producers (n = 15). All box plots are depicted according to Tukey; median (line), IQR (edge of box plot), range (whiskers), 
and outliers 3 times IQR are depicted as dots. P values were calculated by 2-way ANOVA and subsequently by pair-wise 
2-tailed Student’s t test. FC, fold change; PLHIV, people living with HIV; HCs, healthy controls.
1 1
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(7):e145928  https://doi.org/10.1172/jci.insight.145928
Figure 7. Parameters of HIV reservoir, CMV seropositivity, and microbial integrity. (A–D) Log10-transformed CA-DNA in CD4+ cells correlation with (A) circulating 
IL-6 levels, (B) IL-1β production after LPS (100 ng/mL) stimulation, (C) IL-1β production after IMQ (1 μg/mL) stimulation, and (D) soluble CD14 plasma concentra-
tion. (E–H) Log10-transformed CA-RNA in CD4+ cells correlation with (E) circulating IL-6 levels, (F) IL-1β production after LPS stimulation, (G) IL-1β production after 
imiquimod stimulation, and (H) sCD14 plasma concentration. (I–L) Stratified by CMV seropositivity: (I) log10-transformed CA-DNA in CD4+ cells, (J) IL-1β production 
after LPS stimulation, (K) IL-1β production after imiquimod stimulation, and (L) sCD14 plasma concentration. (M) Plasma iFABP, a marker of intestinal integrity, 
between HCs (n = 56) and PLHIV (n = 211). (N–P) Plasma iFABP concentration correlation with (N) IL-1β production after LPS stimulation, (O) IL-1β production after 
imiquimod, and (P) sCD14 plasma concentration. All box plots are depicted according to Tukey; median (line), IQR (edge of box plot), range (whiskers), and outliers 
3 times IQR (dots). Pearson’s coefficient (r) after log transformation is shown in correlation plots. Data in box plots are analyzed using 2-tailed Student’s t test 
after log10 transformation. All plots depict data from PLHIV only (n = 211) unless otherwise stated. CA-DNA, cell-associated HIV-1 DNA; CA-RNA, cell-associated 
HIV-1 RNA; IMQ, imiquimod; iFABP, intestinal fatty acid–binding protein; PLHIV, people living with HIV; HCs, healthy controls.
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defective immunity could contribute to fungal dysbiosis in virally suppressed PLHIV. Hence, our present 
data support the need for future studies exploring the role of  the mycobiome in persistent inflammation in 
PLHIV, as well as possible strategies to reduce β-glucan exposure.
Reducing inflammation is considered an attractive therapeutic target to reduce the burden of  CVDs. 
The Canakinumab Anti-Inflammatory Thrombosis Outcome Study trial was carried out in HIV-uninfected 
subjects who were at risk for a cardiovascular event. The trial revealed that specific neutralization of  IL-1β 
reduced the incidence of  subsequent cardiovascular events and death from lung cancer (60, 61). Similarly, 
the antiinflammatory drug colchicine reduced cardiovascular events in patients with coronary disease (62). 
In contrast, the immunosuppressive drug methotrexate did not reduce CVD, underlining the importance 
of  IL-1β in CVD (63). Recent findings that canakinumab reduced atherosclerotic inflammation in PLHIV 
at high risk for CVD are therefore promising (64) and support the importance of  IL-1β pathway in HIV. 
Orally administrated drugs that inhibit the IL-1β pathway, such as inflammasome inhibitors, may form an 
attractive alternative (65). This also applies to epigenetics modifying drugs, such as histone deacetylase 
inhibitors. These drugs have been shown to reduce CRP concentrations, IL-1β expression in PBMCs (66), 
and IL-1β production to LPS stimulation in whole blood from PLHIV (67). Taken together, our present 
data support the use of  interventions targeting the IL-1β pathway or reduce β-glucan exposure as an adjunc-
tive therapy to reduce non-AIDS–related comorbidities.
A particular strength of  our study is the in-depth functional analysis of  adaptive and innate immune 
cell function in a relatively large cohort of  PLHIV. The same HFGP approach was successfully used to 
investigate genetic, environmental, and microbial factors influencing the immune system in HIV-uninfected 
individuals (21–23, 37). Limitations of  our study are that the age and sex distribution of  the PLHIV and 
control cohorts differed. All analyses were therefore adjusted for these differences using multivariate anal-
yses with sufficient sample size. Moreover, the primary findings were confirmed when we resampled a 
selection of  age- and sex-matched PLHIV and controls. However, we could not correct for men who have 
sex with men, as this information was not available for the control group (68). Second, the nature of  our 
cross-sectional study does not allow us to draw strong causal inferences, for example, on the role of  HIV or 
β-glucan in the observed immune changes. Third, the heterogeneity and activity of  the HIV reservoir is not 
fully determined by HIV CA-DNA and HIV CA-RNA measurement only; residual viremia with single-co-
py assay could quantify recent HIV activity. Fourth, recently, monocyte alterations in PLHIV were linked 
to cART-induced oxidative stress (69). The enrollment in our cohort was limited to virally suppressed 
PLHIV on cART and, therefore, a possible independent effect of  cART on immune responses could not be 
assessed. However, an effect of  different cART regimens appears unlikely because no differences in cyto-
kine responses were found across the different cART regimens. Finally, due to limited inclusion of  women 
in our cohort, generalizability to women or sex-specific analyses were not feasible.
In conclusion, we found that PLHIV on stable cART exhibit a marked and long-lasting increase in 
the production of  IL-1β with subsequent downstream monocyte-derived cytokines, suggesting a trained 
immunity phenotype of  monocytes. Increased translocation of  β-glucan from the gastrointestinal tract was 
identified as a possible inducer of  this innate immune phenotype. Our findings provide mechanistic insights 
and shed new light on the usefulness of  interventions targeting the innate immune system, as well as the gut 
mycobiome, as an adjunctive therapy to reduce non-AIDS–related comorbidities.
Methods
Study population. A total of 211 PLHIV were recruited from the HIV clinic of the Radboud University Medical 
Center between December 2015 and February 2017, with a follow-up measurement in 2018. Caucasian individ-
uals who were 18 years of age or older, were on cART for more than 6 months with an HIV-RNA load greater 
than or equal to 200 copies/mL, and showed no signs of opportunistic infections or active hepatitis B/C were 
included. The control group consisted of 56 healthy individuals not using any medication at inclusion. Inclu-
sion, sampling, and sample processing of both cohorts were conducted simultaneously, and uninfected controls 
were sampled every 3 months during the inclusion of PLHIV. In the follow-up measurement, we resampled 28 
PLHIV, men older than 45 years of age, after more than 1 year and stratified them on the basis of their initial 
IL-1β production capacity in a group of low IL-1β–producers (lowest quartile) and high IL-1β–producers (high-
est quartile). A control group of 14 age- and sex-matched healthy controls was also included. These groups 
were used for monocyte-only RNA expression and β-glucan measurements. All experiments were performed by 
the same personnel using the HFGP methodologies (http://www.humanfunctionalgenomics.org) (19). General 
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Figure 8. β-Glucan induces a proinflammatory phenotype in monocytes. (A) β-Glucan in serum stratified by HCs (control) and PLHIV with low or high 
initial IL-1β response. (B) Percentage of detectable levels of β-glucan in serum, stratified by control and PLHIV with high and low initial IL-1β response. (C 
and D) IL-1β production after 24 hours’ stimulation with imiquimod (C) (1 μg/mL) or Mycobacterium tuberculosis (Mtb) (D) (1 μg/mL) in PLHIV stratified by 
detectable β-glucan levels. (E) IL1B gene expression after imiquimod stimulation depicted as FC from medium (RPMI). (F) Intracellular levels of pro–IL-1β 
protein after imiquimod stimulation. (G and H) IL-1Ra production after 24 hours’ stimulation with imiquimod (G) or Mtb (H) in PLHIV stratified by β-glucan. 
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information from all participants was recorded in an electronic case report form (CastorEDC). Clinical data 
were extracted from the electronic hospital information system and the Stichting HIV Monitoring registry.
Ex vivo PBMC and monocyte stimulation. Venous blood was collected in sterile 10 mL EDTA and 8 mL 
serum BD Vacutainer tubes (Becton Dickinson) and processed within 1–4 hours. Isolation of  PBMCs 
was performed on freshly collected blood by density centrifugation over Ficoll-Paque (VWR) as described 
previously (70). Monocytes were isolated by magnetic-activated cell sorting using negative bead selection 
with the Pan Monocyte Isolation Kit (Miltenyi Biotec) according to manufacturer’s instructions. Cell 
counts, cell purity, and composition were evaluated by XN-450 hematology analyzer (Sysmex Corpora-
tion). Fresh isolated cells (monocytes 1 × 105 cells per well, PBMCs 5 × 105 cells per well) were incubated 
with different bacterial, fungal, and viral stimuli (Supplemental Table 2) at 37°C and 5% CO2 for either 
24 hours or 7 days. For the 7-day stimulation, 10% human pooled serum was added to the wells. IL-1β, 
IL-6, IL-1Ra, IL-10, and TNF-α were determined in the supernatants of  the 24-hour PBMC or monocyte 
stimulation experiments, using ELISAs (Duoset ELISA, R&D Systems). IL-17, IL-22, and IFN-γ were 
measured after the 7-day stimulation of  PBMCs (PeliKine Compact or R&D Systems). For intracellular 
cytokine measurements of  active IL-1β and pro–IL-1β (Quantikine, R&D Systems), cell pellets were 
lysed using Triton X-100 (MilliporeSigma).
Measurements of  plasma markers and immunophenotyping. iFABP, a marker of  enterocyte damage, resistin, 
adiponectin, leptin, IL-18BP, IL-18, hsCRP, sCD14, and sCD163 were measured using ELISA (Duoset or 
Quantikine, R&D Systems). IL-6, TNF-α, IL-10, and IL-1Ra were measured using SimplePlex Cartridges 
(Protein Simple). Levels of  1,3-β-D-glucan (β-glucan) were measured with Fungitell (Associates of  Cape 
Cod) and CMV IgG by ELISA (Genway Biotech). All assays were performed according to manufacturers’ 
recommendations, and samples of  the different cohorts were measured simultaneously in the same plates 
or SimplePlex Cartridges. Monocyte subsets were measured in whole blood on a Navios flow cytometer 
(Beckman Coulter) as described elsewhere. Antibodies used are listed in Supplemental Table 3 (22).
RNA extraction and gene expression. For qPCR analyses, total RNA was extracted from monocyte cell 
pellets (5 × 105 cells) collected in TRIzol (Life Technologies) according to the manufacturer’s instruc-
tions. Subsequently, cDNA was synthesized using iScript reverse transcriptase according to manufacturer’s 
instructions (Invitrogen) with 500 ng RNA input in a 10 μL reaction mix. Relative expression of  genes 
NLRP3, TNF, IL6, and IL1B was measured using SYBR Green assays (Invitrogen) on an Applied Biosci-
ences Step-One PLUS qPCR machine (Thermo Fisher Scientific) withr eaction volumes of  10 μL with 2 
μL cDNA input. Normalization was performed using ΔΔCt based on 2 (18S and B2M) reference genes 
that were stable after stimulation. Cycling conditions were 95°C for 10 minutes, 40 cycles at 95°C for 15 
seconds, 60°C for 1 minute, followed by dissociation curve analysis. Primers were designed to be intron 
spanning and are listed in Supplemental Table 4.
For transcriptome analysis by RNA-Seq, total RNA was extracted from monocytes (5 × 105) using the 
QIAGEN RNeasy RNA extraction kit, using on-column DNase treatment. Next, ribosomal RNA removal 
and library preparation for next-generation RNA-Seq were achieved utilizing KAPA RNA HyperPrep Kit 
with RiboErase (Roche), following the manufacturer’s protocol. The integrity and quality of  prepared librar-
ies were assessed using Agilent 2100 Bioanalyzer. Sequencing was performed using Illumina NextSeq 500 
machine in a paired-end sequencing fashion. Sequencing reads obtained from RNA-Seq measurement were 
aligned to the hg38 human genome reference using STAR (71). A lower cutoff  of  average 50 reads among 
all samples was used to designate a gene as being expressed in our cohort. R software and DESeq2 differ-
ential analysis package (72) were used to normalize and assess differentially expressed genes, utilizing FDR 
5% and log2(fold change) greater than 1 as the significance cutoff. The network of  genes connected to their 
corresponding gene ontology was generated using cytoscape (73). The processed RNA-Seq data including 
normalized read counts can be accessed via the National Center for Biotechnology Information’s Gene 
Expression Omnibus database (GSE160184).
(I and J) IL-6 production after 24 hours’ stimulation with imiquimod (I) or Mtb (J) in PLHIV stratified by β-glucan. (K and L) TNF-α production after 24 hours’ 
stimulation with imiquimod (K) or Mtb (L) in PLHIV stratified by β-glucan. (A–L) PLHIV, n = 28; HCs, n = 14. All box plots are depicted according to Tukey; 
median (line), IQR (edge of box plot), range (whiskers), and outliers 3 times IQR are depicted as dots. Data were analyzed using 2-tailed Student’s t test 
after log10 transformation. (M) Initial training with LPS, β-glucan (10 μg/mL), or medium only (RPMI plus 10% serum) was performed for 24 hours on day 1. 
Thereafter, a 5-day resting period in medium only (supplemented by 10% serum); on day 6, adherent monocytes were restimulated with LPS 10 ng/mL. IL-6 
was measured in the supernatant and FC from training with medium only are depicted. Data are from 3 separate experiments (n = 9). Data were analyzed 
using Wilcoxon matched pairs signed-rank test. *P < 0.05 **P < 0.01. IMQ, imiquimod; FC, fold change.
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HIV reservoir quantification. HIV-1 CA-DNA and CA-RNA were measured in triplicate by droplet digital 
PCR (ddPCR QX200 — Bio-Rad) (Supplemental Table 3) in CD4+ T cells isolated using EasySep Human 
CD4+ T Cell Isolation Kit (STEMCELL Technologies) as previously described (74). Briefly, genomic DNA 
was extracted using the DNeasy Blood & Tissue Kit (QIAGEN) according to the manufacturer’s protocol, 
with an additional step of  adding 75 μL elution buffer on the column heated at 56°C for 10 minutes. CA-RNA 
was extracted using the Innuprep RNA kit (Westburg) with 30 μL elution buffer. Total RNA was reversely 
transcribed to cDNA by qScript cDNA SuperMix according to manufacturer’s protocol (Quantabio). Before 
PCR amplification, genomic DNA was restricted by EcoRI (Promega), and cycling conditions were imple-
mented as described previously (74). Total HIV-1 DNA measurements were normalized by measuring the 
reference gene RPP30 (Supplemental Table 4) in duplicate by ddPCR and expressed per million PBMCs. 
CA-RNA was normalized using 3 reference genes per patient (B2M, ACTB, and GADPH), which were mea-
sured with LightCycler 480 SYBR Green Master Mix (Bio-Rad). HIV-1 RNA copies were divided by the 
geometric mean of  the reference genes and expressed per million PBMCs. Droplet classification and absolute 
quantification were performed using the ddpcRquant analysis tool with standard settings (75).
Statistics. Depending on normality, log10- or inverse rank-based transformation was applied. Values out-
side the assay quantification limits were imputed at the respective limit. Parameters for which one of  the 
detection limits contained greater than 50% of the measurements were excluded. Comparisons in baseline 
characteristics between groups were made using 2-tailed Student’s t test or Mann-Whitney U test depending 
on data distribution. Differences in noncontinuous data were analyzed by the Pearson’s χ2 test or Fisher’s exact 
test in case of  expected counts less than 5. Data were analyzed using a linear regression model. The crude 
model included an adjustment for sampling time and the primary analyses included age, sex, and seasonality 
as covariates. A P value less than 0.05 was considered statistically significant, and correction for multiple 
testing was applied using the Benjamini-Hochberg method (FDR correction). Data were analyzed using R.
Study approval. The study protocol was approved by the Medical Ethical Review Committee region Arn-
hem-Nijmegen (CMO2012-550), and experiments were conducted in accordance with the principles of  the 
Declaration of  Helsinki. Written informed consent was obtained from all participants.
Author contributions
WAVDH, LVDW, QDM, MGN, LABJ, and AJAMVDV designed the study. WAVDH, LVDW, and MJ recruit-
ed and included the participants. WAVDH, LVDW, MJ, WT, FK, and SR performed the laboratory experiments. 
WAVDH, RTH, FK, and LVDW analyzed the data and interpreted the data together with QDM, AJAMVDV, 
MGN, CAD, LV, PEV, HJPMK, HGS, IJ, and JVL. WAVDH, LVDW, AJAMVDV, and QDM wrote the manu-
script. All authors have read and contributed significantly to the final manuscript. The co–first authors are listed 
alphabetically. QDM was listed last in the author list as he supervised the final stages of the project.
Acknowledgments
We thank all participants in the study. This study was supported by a grant from Aidsfonds Netherlands. MGN 
was supported by an ERC Advanced grant (833247) and a Spinoza grant of the Netherlands Organization for 
Scientific Research. LV was supported by the Research Foundation — Flanders (FWO, grant 1.8.020.09.N.00) 
and a Collen-Francqui Research Professor Mandate. SR received a strategic basic research fund of FWO 
(1S32916N). CAD was supported by NIH grant AI-15614.
Address correspondence to: Wouter A. van der Heijden, Department of Internal Medicine, Radboud University 
Medical Center, 6500 HB, Nijmegen, the Netherlands. Phone: 31.0.243611111; Email: Wouter.vanderHeijden 
@radboudumc.nl.
 1. Deeks SG, et al. Systemic effects of  inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633–645.
 2. Hunt PW, et al. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214(suppl 2):S44–S50.
 3. INSIGHT START Study Group, et al. Initiation of  antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 
2015;373(9):795–807.
 4. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. CD4+ count-guided interruption of antiretroviral 
treatment. New Engl J Med. 2006;355(22):2283–2296.
 5. Freeman ML, et al. Cytokines and T-cell homeostasis in HIV infection. J Infect Dis. 2016;214(suppl 2):S51–S57.
 6. Rogacev KS, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of  951 patients 
referred for elective coronary angiography. J Am Coll Cardiol. 2012;60(16):1512–1520.
1 6
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(7):e145928  https://doi.org/10.1172/jci.insight.145928
 7. Sandler NG, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–790.
 8. McKibben RA, et al. Elevated levels of  monocyte activation markers are associated with subclinical atherosclerosis in men with 
and those without HIV infection. J Infect Dis. 2015;211(8):1219–1228.
 9. Brenchley JM, et al. Microbial translocation is a cause of  systemic immune activation in chronic HIV infection. Nat Med. 
2006;12(12):1365–1371.
 10. Gianella S, Letendre S. Cytomegalovirus and HIV: a dangerous pas de deux. J Infect Dis. 2016;214(Suppl 2):S67–S74.
 11. Hatano H. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS. 
2013;8(3):211–216.
 12. Hatano H, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients 
with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis. 2013;208(9):1436–1442.
 13. Netea MG, et al. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011;9(5):355–361.
 14. Netea MG, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375–388.
 15. Novakovic B, et al. β-glucan reverses the epigenetic state of  LPS-induced immunological tolerance. Cell. 2016;167(5):1354–1368.
 16. Saeed S, et al. Epigenetic programming of  monocyte-to-macrophage differentiation and trained innate immunity. Science. 
2014;345(6204):1251086.
 17. Dye CK, et al. Comparative DNA methylomic analyses reveal potential origins of  novel epigenetic biomarkers of  insulin resistance 
in monocytes from virally suppressed HIV-infected adults. Clin Epigenetics. 2019;11(1):95.
 18. Bekkering S, et al. Trained innate immunity and atherosclerosis. Curr Opin Lipidol. 2013;24(6):487–492.
 19. Netea MG, et al. Understanding human immune function using the resources from the Human Functional Genomics Project. 
Nat Med. 2016;22(8):831–833.
 20. Schirmer M, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167(4):1125–1136.
 21. Ter Horst R, et al. Host and environmental factors influencing individual human cytokine responses. Cell. 2016;167(4):1111–1124.
 22. Aguirre-Gamboa R, et al. Differential effects of  environmental and genetic factors on T and B cell immune traits. Cell Rep. 
2016;17(9):2474–2487.
 23. Li Y, et al. Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi. Nat Med. 2016;22(8):952–960.
 24. Kapellos TS, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019;10:2035.
 25. Dinarello CA. Overview of  the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27.
 26. Chomont N, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 
2009;15(8):893–900.
 27. Pasternak AO, et al. Cell-associated HIV RNA: a dynamic biomarker of  viral persistence. Retrovirology. 2013;10:41.
 28. Mehraj V, et al. Circulating (1→3)-β-D-glucan is associated with immune activation during human immunodeficiency virus 
infection. Clin Infect Dis. 2020;70(2):232–241.
 29. Bekkering S, et al. In vitro experimental model of  trained innate immunity in human primary monocytes. Clin Vaccine Immunol. 
2016;23(12):926–933.
 30. Hernandez JC, et al. HIV type 1 infection up-regulates TLR2 and TLR4 expression and function in vivo and in vitro. AIDS Res 
Hum Retroviruses. 2012;28(10):1313–1328.
 31. Merlini E, et al. Stimulation of  PBMC and monocyte-derived macrophages via toll-like receptor activates innate immune pathways 
in HIV-infected patients on virally suppressive combination antiretroviral therapy. Front Immunol. 2016;7:614.
 32. Tsai A, et al. Toll-like receptor 7 agonist GS-9620 induces HIV expression and HIV-specific immunity in cells from HIV-infected 
individuals on suppressive antiretroviral therapy. J Virol. 2017;91(8):e02166–16.
 33. Sachdeva N, et al. Impaired restoration of plasmacytoid dendritic cells in HIV-1-infected patients with poor CD4 T cell reconstitution 
is associated with decrease in capacity to produce IFN-alpha but not proinflammatory cytokines. J Immunol. 2008;181(4):2887–2897.
 34. Espindola MS, et al. Epigenetic alterations are associated with monocyte immune dysfunctions in HIV-1 infection. Sci Rep. 
2018;8(1):5505.
 35. Bordoni V, et al. In HIV-infected patients, some differential alterations of CD4 and CD8 T cell homeostasis may not be restored by ≥ 7 
years of highly active antiretroviral therapy, in spite of good CD4 T cell repopulation. J Antimicrob Chemother. 2012;67(7):1802–1804.
 36. Mendez-Lagares G, et al. Differential alterations of  the CD4 and CD8 T cell subsets in HIV-infected patients on highly active 
antiretroviral therapy with low CD4 T cell restoration. J Antimicrob Chemother. 2012;67(5):1228–1237.
 37. Schirmer M, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167(7):1897.
 38. Bowman ER, et al. Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid 
profiles and activation indices: a model for studying atherogenic mechanisms. PLoS Pathog. 2020;16(10):1008869.
 39. Bekkering S, et al. Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis 
in humans in vivo. Atherosclerosis. 2016;254:228–236.
 40. Bekkering S, et al. Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell Metab. 
2019;30(1):1–2.
 41. Noz MP, et al. Trained immunity characteristics are associated with progressive cerebral small vessel disease. Stroke. 
2018;49(12):2910–2917.
 42. Christ A, et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell. 2018;172(1–2):162–175.
 43. Rickabaugh TM, et al. Acceleration of age-associated methylation patterns in HIV-1-infected adults. PLoS One. 2015;10(3):0119201.
 44. Nelson KN, et al. Identification of  HIV infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive, 
treatment-naive U.S. veterans. AIDS. 2017;31(4):571–575.
 45. Zhang X, et al. Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals. Epigenetics. 
2016;11(10):750–760.
 46. Sundermann EE, et al. Inflammation-related genes are associated with epigenetic aging in HIV. J Neurovirol. 2019;25(6):853–865.
 47. Chen J, et al. Epigenetic associations with estimated glomerular filtration rate among men with human immunodeficiency virus 
infection. Clin Infect Dis. 2020;70(4):667–673.
 48. Mathur R, et al. DNA methylation markers of  Type 2 Diabetes mellitus among male veterans with or without human immuno-
deficiency virus infection. J Infect Dis. 2019;219(12):1959–1962.
1 7
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(7):e145928  https://doi.org/10.1172/jci.insight.145928
 49. Vaccari M, et al. HIV vaccine candidate activation of  hypoxia and the inflammasome in CD14+ monocytes is associated with  
a decreased risk of  SIVmac251 acquisition. Nat Med. 2018;24(6):847–856.
 50. Periyasamy P, et al. Epigenetic promoter DNA methylation of  mir-124 promotes HIV-1 Tat-mediated microglial activation via 
MECP2-STAT3 axis. J Neurosci. 2018;38(23):5367–5383.
 51. Mitroulis I, et al. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell. 2018;172(1–2):147–161.
 52. Morris A, et al. Serum (1→3)-β-D-glucan levels in HIV-infected individuals are associated with immunosuppression, inflammation, 
and cardiopulmonary function. J Acquir Immune Defic Syndr. 2012;61(4):462–468.
 53. Hoenigl M, et al. (1→3)-β-D-glucan levels correlate with neurocognitive functioning in HIV-infected persons on suppressive 
antiretroviral therapy: a cohort study. Medicine (Baltimore). 2016;95(11):e3162.
 54. Kim CJ, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of  systemic immune 
activation. J Immunol. 2013;191(5):2164–2173.
 55. Hernandez-Santos N, et al. Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections.  
Mucosal Immunol. 2013;6(5):900–910.
 56. Mudd JC, Brenchley JM. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression.  
J Infect Dis. 2016;214(Suppl 2):S58–S66.
 57. Brenchley JM. Microbial translocation is a cause of  systemic immune activation in chronic HIV infection. Nat Med. 
2006;12(12):1365–1371.
 58. Sereti I, et al. Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. 
Clin Infect Dis. 2017;64(2):124–131.
 59. Chin VK, et al. Mycobiome in the gut: a multiperspective review. Mediators Inflamm. 2020;2020:9560684.
 60. Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
 61. Ridker PM, et al. Effect of  interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: 
exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–1842.
 62. Nidorf  SM, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847.
 63. Ridker PM, et al. Low-dose methotrexate for the prevention of  atherosclerotic events. N Engl J Med. 2019;380(8):752–762.
 64. Hsue PY, et al. IL-1β inhibition reduces atherosclerotic inflammation in HIV infection. J Am Coll Cardiol. 2018;72(22):2809–2811.
 65. Abbate A, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260–1280.
 66. Hogh Kolbaek Kjaer AS, et al. The histone deacetylase inhibitor panobinostat lowers biomarkers of  cardiovascular risk and 
inflammation in HIV patients. AIDS. 2015;29(10):1195–1200.
 67. Brinkmann CR, et al. Treatment of HIV-infected individuals with the histone deacetylase inhibitor panobinostat results in increased 
numbers of regulatory T cells and limits ex vivo lipopolysaccharide-induced inflammatory responses. mSphere. 2018;3(1):e00616–17.
 68. Palmer CD, et al. Enhanced immune activation linked to endotoxemia in HIV-1 seronegative MSM. AIDS. 2014;28(14):2162–2166.
 69. Singh MV, et al. Senescent phenotype induced by p90RSK-NRF2 signaling sensitizes monocytes and macrophages to oxidative 
stress in HIV-positive individuals. Circulation. 2019;139(9):1199–1216.
 70. Oosting M, et al. Borrelia-induced cytokine production is mediated by spleen tyrosine kinase (Syk) but is Dectin-1 and Dectin-2 
independent. Cytokine. 2015;76(2):465–472.
 71. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
 72. Love MI, et al. Moderated estimation of  fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
 73. Shannon P, et al. Cytoscape: a software environment for integrated models of  biomolecular interaction networks. Genome Res. 
2003;13(11):2498–2504.
 74. Rutsaert S, et al. Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy. 
J Antimicrob Chemoth. 2019;74(10):3030–3034.
 75. Trypsteen W, et al. ddpcRquant: threshold determination for single channel droplet digital PCR experiments. Anal Bioanal Chem. 
2015;407(19):5827–5834.
 76. Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control 
and Prevention. Frequently Asked Questions. http://www.cdc.gov/alcohol/faqs.htm#heavyDrinking. Accessed April 22, 2020.
